SRR8518219
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.530
- G2M_CHECKPOINT+0.480
- INTERFERON_ALPHA_RESPONSE+0.410
- OXIDATIVE_PHOSPHORYLATION+0.380
- INTERFERON_GAMMA_RESPONSE+0.250
- MITOTIC_SPINDLE+0.250
- DNA_REPAIR+0.240
- SPERMATOGENESIS+0.140
Top 10 suppressed
- ANGIOGENESIS-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- CHOLESTEROL_HOMEOSTASIS-0.410
- COAGULATION-0.400
- MYOGENESIS-0.400
- APICAL_JUNCTION-0.360
- TGF_BETA_SIGNALING-0.360
- APICAL_SURFACE-0.350
- COMPLEMENT-0.300
- ANDROGEN_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454749 | — | F | 0.929 |
| 2 | SRR2016966 | — | — | 0.899 |
| 3 | TCGA-OL-A6VO-01A-12R-A33J-07 | — | E | 0.894 |
| 4 | TCGA-66-2757-01A-01R-0851-07 | — | cohortMD1 | 0.891 |
| 5 | SRR8518168 | — | E | 0.888 |
| 6 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.888 |
| 7 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.886 |
| 8 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.876 |
| 9 | TCGA-21-1083-01A-01R-0692-07 | — | cohortMD1 | 0.869 |
| 10 | SRR33532781 | — | D | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |